Company intelligence / Profile preview

RCT Logic

United States

Ownership: Private
Development stage: Other

Overview

RCT Logic was a company founded in 2008 that specialized in licensing the Sequential Parallel Comparison Design (SPCD) clinical trial methodology to pharmaceutical and biotech companies. This technology, licensed exclusively from Massachusetts General Hospital, aimed to improve trial efficiency and reduce placebo effects. In 2014, PPD acquired the exclusive license for the SPCD patent portfolio, leading to RCT Logic's subsequent inactivity.

Therapeutic areas: PsychiatryNeurology
Industry: Contract Research Organization

Partnerships

Massachusetts General Hospital (MGH)PPDNational Institutes of Health (NIH)

Beyond the preview

Go deeper on RCT Logic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RCT Logic.

Explore the full profile